[{"data":1,"prerenderedAt":255},["ShallowReactive",2],{"drug-ceftazidime-avibactam":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":23,"regimens":38,"contraindications":141,"warnings":151,"renal":159,"monitoring":169,"interactions":170,"review":171,"examples":174,"atc":199,"iran":201,"usApproval":208,"links":214,"populations":229},"ceftazidime-avibactam",1,{"fa":7,"en":8},"سفتازیدیم-آویباکتام","Ceftazidime-avibactam","anti-infectives",{"fa":11,"en":12},"سفالوسپورین + مهارکننده بتالاکتاماز","Cephalosporin + beta-lactamase inhibitor",[14],{"name":15,"market":16},"Avycaz","US",[18,19,20,21,22],"avycaz","zavicefta","آویکاز","زاویسفتا","سفتازیدیم آویباکتام",[24],{"id":25,"form":26,"route":27,"label":28,"concentration":29,"markets":33,"refs":34},"vial-2-5","powder-for-injection","iv","2.5 g vial (ceftazidime 2 g + avibactam 0.5 g)",{"amount":30,"unit":31,"perUnit":32},2500,"mg","vial",[16],[35],{"source":36,"section":37},"fda-avycaz","3",[39,68,95,117],{"id":40,"disease":41,"label":42,"population":45,"type":49,"unit":31,"dose":50,"refs":52,"durationDays":55,"notes":58},"adult","intra-abdominal-infection",{"fa":43,"en":44},"عفونت عارضه‌دار داخل شکم، ادراری (پیلونفریت) و پنومونی بیمارستانی\u002Fونتیلاتور — بزرگسال ۲٫۵ g هر ۸ ساعت","Complicated intra-abdominal and urinary infections (pyelonephritis), HABP\u002FVABP — adult 2.5 g every 8 h",{"minAge":46},{"value":47,"unit":48},18,"year","fixed",{"perDose":30,"dosesPerDay":51},3,[53],{"source":36,"section":54},"2.1, Table 1",{"min":56,"max":57},5,14,[59],{"text":60,"refs":63},{"fa":61,"en":62},"دوز به‌صورت مجموع سفتازیدیم + آویباکتام (۴:۱). انفوزیون ۲ ساعته هر ۸ ساعت. cIAI همراه مترونیدازول. مدت: cIAI ۵ تا ۱۴، cUTI و پنومونی ۷ تا ۱۴ روز.","Dose as total ceftazidime + avibactam (4:1). 2-hour infusion every 8 h. cIAI with metronidazole. Duration: cIAI 5–14, cUTI and pneumonia 7–14 days.",[64,66],{"source":36,"section":65},"2.1",{"source":36,"section":67},"2.2",{"id":69,"disease":41,"label":70,"population":73,"type":78,"unit":31,"dose":79,"refs":82,"limits":85,"durationDays":88,"notes":89},"child",{"fa":71,"en":72},"کودک ۶ ماه تا \u003C۱۸ سال — ۶۲٫۵ mg\u002Fkg هر ۸ ساعت (حداکثر ۲٫۵ g)","Children 6 months to \u003C18 years — 62.5 mg\u002Fkg every 8 h (max 2.5 g)",{"minAge":74,"maxAge":77},{"value":75,"unit":76},6,"month",{"value":47,"unit":48},"weightBased",{"perKgPerDose":80,"intervalHours":81},62.5,8,[83],{"source":36,"section":84},"2.2, Table 2",{"maxPerDose":30,"refs":86},[87],{"source":36,"section":84},{"min":56,"max":57},[90],{"text":91,"refs":92},{"fa":61,"en":62},[93,94],{"source":36,"section":65},{"source":36,"section":67},{"id":96,"disease":41,"label":97,"population":100,"type":78,"unit":31,"dose":103,"refs":105,"limits":107,"durationDays":110,"notes":111},"infant",{"fa":98,"en":99},"شیرخوار ۳ تا \u003C۶ ماه — ۵۰ mg\u002Fkg هر ۸ ساعت","Infants 3 to \u003C6 months — 50 mg\u002Fkg every 8 h",{"minAge":101,"maxAge":102},{"value":51,"unit":76},{"value":75,"unit":76},{"perKgPerDose":104,"intervalHours":81},50,[106],{"source":36,"section":84},{"maxPerDose":30,"refs":108},[109],{"source":36,"section":84},{"min":56,"max":57},[112],{"text":113,"refs":114},{"fa":61,"en":62},[115,116],{"source":36,"section":65},{"source":36,"section":67},{"id":118,"disease":41,"label":119,"population":122,"type":78,"unit":31,"dose":127,"refs":129,"limits":131,"durationDays":134,"notes":135},"young",{"fa":120,"en":121},"شیرخوار بالای ۲۸ روز تا \u003C۳ ماه — ۳۷٫۵ mg\u002Fkg هر ۸ ساعت","Infants >28 days to \u003C3 months — 37.5 mg\u002Fkg every 8 h",{"minAge":123,"maxAge":126},{"value":124,"unit":125},29,"day",{"value":51,"unit":76},{"perKgPerDose":128,"intervalHours":81},37.5,[130],{"source":36,"section":84},{"maxPerDose":30,"refs":132},[133],{"source":36,"section":84},{"min":56,"max":57},[136],{"text":137,"refs":138},{"fa":61,"en":62},[139,140],{"source":36,"section":65},{"source":36,"section":67},[142],{"id":143,"severity":144,"text":145,"refs":148},"hyper","block",{"fa":146,"en":147},"حساسیت جدی به سفتازیدیم، آویباکتام، فرآورده‌های حاوی آویباکتام یا سایر سفالوسپورین‌ها.","Serious hypersensitivity to ceftazidime, avibactam, avibactam-containing products or other cephalosporins.",[149],{"source":36,"section":150},"4",[152],{"text":153,"refs":156},{"fa":154,"en":155},"کاهش پاسخ بالینی در cIAI با ClCr ۳۰ تا ۵۰؛ حساسیت (واکنش متقاطع با پنی‌سیلین)؛ اسهال C. difficile؛ سمیت عصبی (تشنج، انسفالوپاتی) در نارسایی کلیه بدون تنظیم دوز.","Decreased clinical response in cIAI with CrCl 30–50; hypersensitivity (penicillin cross-reactivity); C. difficile diarrhoea; neurotoxicity (seizures, encephalopathy) with unadjusted renal impairment.",[157],{"source":36,"section":158},"5",[160],{"egfrBelow":161,"severity":162,"text":163,"refs":166},51,"warn",{"fa":164,"en":165},"ClCr ۵۰ و کمتر: ۳۱ تا ۵۰ → ۱٫۲۵ g هر ۸ ساعت؛ ۱۶ تا ۳۰ → ۰٫۹۴ g هر ۱۲ ساعت؛ کمتر طبق جدول ۳. کودک زیر ۲ سال با نارسایی کلیه: داده کافی نیست.","CrCl ≤50: 31–50 → 1.25 g every 8 h; 16–30 → 0.94 g every 12 h; lower per Table 3. Children under 2 with renal impairment: insufficient data.",[167],{"source":36,"section":168},"2.3",[],[],{"status":172,"reviewer":173,"date":173},"unverified",null,[175,179,185,188,193],{"regimen":40,"formulation":25,"input":176,"expect":178},{"ageYears":104,"weightKg":177},70,{"perDose":30,"dosesPerDay":51},{"regimen":69,"formulation":25,"input":180,"expect":183},{"ageYears":181,"weightKg":182},2,10,{"perDose":184},625,{"regimen":69,"formulation":25,"input":186,"expect":187},{"ageYears":57,"weightKg":104},{"perDose":30},{"regimen":96,"formulation":25,"input":189,"expect":191},{"ageYears":190,"weightKg":75},0.4,{"perDose":192},300,{"regimen":118,"formulation":25,"input":194,"expect":197},{"ageYears":195,"weightKg":196},0.15,4,{"perDose":198},150,[200],"J01DD52",{"status":202,"refs":203},"not-found",[204],{"source":205,"section":206,"url":207},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Ceftazidime-avibactam",{"kind":209,"refs":210,"id":213},"NDA",[211],{"source":36,"section":212},"SPL approval \u002F marketing category","NDA206494",[215,218,222,226],{"kind":216,"url":217,"label":213},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=206494",{"kind":219,"url":220,"label":221},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd","FDA Avycaz",{"kind":223,"url":224,"label":225},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa615018.html","Ceftazidime and Avibactam Injection",{"kind":227,"url":228,"label":200},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J01DD52",{"pregnancy":230,"pediatric":239,"geriatric":247},{"level":231,"text":232,"quote":235,"refs":236},"caution",{"fa":233,"en":234},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate and well-controlled studies of AVYCAZ, ceftazidime, or avibactam in pregnant women.",[237],{"source":36,"section":238},"8.1",{"level":231,"text":240,"quote":243,"refs":244},{"fa":241,"en":242},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of AVYCAZ in the treatment of cUTI, cIAI, and HABP\u002FVABP have been established in pediatric patients at least 31 weeks gestational age and older.",[245],{"source":36,"section":246},"8.4",{"level":231,"text":248,"quote":251,"refs":252},{"fa":249,"en":250},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.",[253],{"source":36,"section":254},"8.5",1792444386928]